Kolexia
Maubeuge Nicolas Neurologie
Maubeuge Nicolas
Neurologie
Hôpital La Miletrie
Poitiers, France
41 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sclérose en plaques Sclérose Sclérose en plaques récurrente-rémittente Sclérose en plaques chronique progressive Myélite Polyradiculoneuropathie Leucoencéphalopathie multifocale progressive Polyradiculonévrite inflammatoire démyélinisante chronique Polyneuropathies

Collaborateurs

Voir plus
Ciron Jonathan
Ciron Jonathan
Hôpital Purpan, Toulouse, France
Ruet Aurelie
Ruet Aurelie
Hôpital Pellegrin, Bordeaux, France
Bourre Bertrand
Bourre Bertrand
Hôpital Charles Nicolle, Rouen, France
Labauge Pierre
Labauge Pierre
Hôpital Gui de Chauliac, Montpellier, France

Industries

Voir plus
Biogen
12 collaboration(s)
Dernière en 2022
Merck-Serono
11 collaboration(s)
Dernière en 2023
Novartis
5 collaboration(s)
Dernière en 2023
Janssen
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
NeurofilMS: Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Essai Clinique (CHU Nîmes)   03 mai 2023
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
Multiple sclerosis (Houndmills, Basingstoke, England)   14 décembre 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Neurology   17 août 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.
BMC medical research methodology   30 mai 2022
Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.
Multiple sclerosis (Houndmills, Basingstoke, England)   12 novembre 2021
CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments.
Neurology(R) neuroimmunology & neuroinflammation   02 novembre 2021
Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system
Multiple sclerosis (Houndmills, Basingstoke, England) Congress 2021   12 octobre 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
CNS drugs   18 septembre 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.
Multiple sclerosis and related disorders   08 mai 2021
Autologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyneuropathy.
La Revue de medecine interne   25 mars 2021